Iressa linked to tumour haemorrhage, warns AstraZeneca

Author：

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1132, 2006-01, pp. : 1-1

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

AstraZeneca's lung cancer agent gefitinib [`Iressa'] is being launched at a 25% discount to the chronic myeloid leukaemia agent imatinib mesylate

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 412, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

An agreement reached with AstraZeneca will allow

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 387, 2002-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

AstraZENeca and the A&RT of metadata maintenance

By Frost Paul A A.

Pharmaceutical Programming, Vol. 3, Iss. 2, 2010-12 ,pp. : 57-63

Maney Publishing

Access to resources Recommend Favorite

Molecular pathology in oncology – the AstraZeneca perspective

By Campbell David A Carmichael James Chopra Rajesh

Pharmacogenomics, Vol. 5, Iss. 8, 2004-12 ,pp. : 1167-1173

Future Medicine

Access to resources Recommend Favorite

AstraZeneca's rosuvastatin up against Pfizer's atorvastatin in the US

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 426, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite